biologic therapy
Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
... a biologic at the time of the enrolment ...a biologic at the enrolment visit or were already receiving a biologic therapy at time of enrol- ...
10
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study
... biological therapy effectiveness in RA, we first describe the lifetime course of health status in RA and then the 10-year observed course of health status in RA patients in order to pro- vide information about RA ...
12
Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations
... There are important safety issues with the use of biologic therapy, not least because their targets in the immune system have a role in the body’s defence against infection and malignancy. Difficulties ...
19
Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy
... anti-TNF-α therapy on autophagy may be responsible for its associated in- crease of infection risk, particularly tuberculosis ...anti-IL-6R therapy is also similar to previ- ous reports that anti-IL6R ...
11
Treatment patterns and costs for anti TNFα biologic therapy in patients with psoriatic arthritis
... of therapy groups are not clear, but may be influenced by dissimilarities in response to anti- TNFα biologic therapy, comorbidities, health insurance, change of physician, adverse events (AEs), ...
11
Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
... Abstract: Significant advances in the treatment of rheumatoid arthritis (RA) have been made over the past 10 years with the introduction of biologic therapies, such as the TNF inhibitors. With these medications, ...
10
Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis
... 20 biologic-naïve ...α therapy, and levels of total cholesterol, LDL-C, and triglyceride increased in tocilizumab-treated ...under biologic therapy but was unchanged in biologic-naïve ...
13
Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy
... nately therapy adverse events were not captured in this ...of biologic therapy has brought improve- ments in visual outcomes for children with uveitis ...
9
Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy
... IV therapy after receiving this therapy compared with their recollection of how they felt about it before receiving IV ...SC biologic therapy ...best therapy was for the patients and ...
11
Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey
... Results: A total of 1,920 patients were identified. The mean SIFRA score was 14.21, and 7.05 (49.57%) of the mean composed of clinical and functional status variables, followed by 6.32 (44.47%) for medications, 0.48 ...
7
Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
... TAilored BIOlogic therapy ...combination therapy with ...non-anti-TNF biologic is ...non-anti-TNF biologic is advisable in patients experiencing ...
15
Biologic therapy for autoimmune diseases: an update
... In a study of patients with RA who were not responsive to MTX, (GO-FORWARD study [38]) the efficacy of MTX plus placebo, MTX plus golimumab 50 mg, MTX plus golilumab 100 mg, or golimumab 100 mg plus pla- cebo, were ...
12
Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
... aforementioned factors may serve as a more practical basis on which to select therapy. The current study explores which of these attributes contribute to the discontinuation of SQ anti-TNF treatment (specifically ...
11
Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice
... bDMARD therapy (n = 926), even if 1,438 patients had moderate-to-severe RA and were considered potentially eligible for bDMARD at the initiation of current ...quent biologic treatment, including a decline ...
8
Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?
... all biologic DMARDs (with the possible exception of infliximab and golimumab) have similar efficacy, thus can be selected without reference to their effect on radiographic ...
7
Biologic therapy and tuberculosis: our experience and review of literature
... Particularly, we report the case of a 37-year-old man, a patient affected by a severe form of psoriasis refractory to the traditional drugs (oral retinoids, psoralen and ultraviolet A therapy, and cyclosporin) ...
5
In-/off-label use of biologic therapy in systemic lupus erythematosus
... In recent times, hope was raised in systemic lupus ery- thematosus (SLE) for biologic therapies that are capable of specific molecular targeting at distinct key points. Novel therapies tested in SLE comprise ...
6
BIOLOGIC ARMAMENTARIUM IN PSORIASIS
... Biologic therapy contains protein biomolecules which are manufactured by living ...available biologic for psoriasis treatment specifically targets T-cell, APCs and inflammatory mediator ...of ...
8
Update on the use of systemic biologic agents in the treatment of noninfectious uveitis
... Although biologics have great potential in the treatment of uveitis, the application of biologic therapy has been hampered by several factors. First, uveitis is relatively rare compared with immune-mediated ...
15
Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
... new biologic therapy, SQ MTX, or oral ...hierarchy: biologic or novel small molecule (tofacitinib) (referred to hereafter as the “biologic” arm), SQ MTX, and oral ...a biologic and MTX ...
11